Glaukos Corporation
GKOS
Rangering i aksjer
#2027
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Aksjekurs
$174.03
Sist synkronisert: 2026-10-20
Markedsverdi
$10.26B
Endring (1 dag)
4.34%
Endring (1 år)
129.35%
Land
US
Handel Glaukos Corporation (GKOS)
Kategori
Healthcare
Antall utestående aksjer for Glaukos Corporation (GKOS)
Antall utestående aksjer per June 2026: 58.42M
Ifølge Glaukos Corporation sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 58.42M. Ved slutten av December 2023 hadde selskapet 48.43M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Glaukos Corporation (GKOS) fra 2012 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 58.42M | 10.74% |
| 2024 | 52.76M | 8.92% |
| 2023 | 48.43M | 2.08% |
| 2022 | 47.44M | 2.20% |
| 2021 | 46.42M | 4.33% |
| 2020 | 44.50M | 19.12% |
| 2019 | 37.36M | 6.72% |
| 2018 | 35.00M | 1.81% |
| 2017 | 34.38M | 4.41% |
| 2016 | 32.93M | 88.44% |
| 2015 | 17.47M | -29.78% |
| 2014 | 24.89M | 0.00% |
| 2013 | 24.89M | 1,153.02% |
| 2012 | 1.99M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 1.74B | 2,883.70% |
US
|
|
| 1.28B | 2,094.66% |
IE
|
|
| 383.50M | 556.46% |
US
|
|
| 1.48B | 2,429.31% |
US
|
|
| - | - |
DE
|
